The pharmacovigilance program on natalizumab in Italy: 2 Years of experience

G. Tedeschi, M. P. Amato, R. D'Alessandro, F. Drago, C. Milanese, P. Popoli, P. Rossi, G. Savettieri, M. R. Tola, N. Vanacore, A. Covezzoli, M. De Rosa, G. Comi, Carlo Pozzilli, Antonio Bertolotto, Maria Giovanna Marrosu, Luigi M E Grimaldi, C. Piccinni, N. Montanaro, Laura PeriottoRosamaria Iommelli, Antonio Addis, Nello Martini, L. Provinciali, G. L. Mancardi

Research output: Contribution to journalArticle

Abstract

At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients treated with natalizumab interrupted, for various different reasons, the therapy. Treatment was well tolerated and side effects were similar to those reported in the registrative studies. The majority of treated cases are stable or ameliorated.

Original languageEnglish
JournalNeurological Sciences
Volume30
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2009

Fingerprint

Pharmacovigilance
Italy
Therapeutics
Interferon-beta
Neurology
Multiple Sclerosis
Natalizumab
Databases
Recurrence
Pharmaceutical Preparations

Keywords

  • Multiple sclerosis
  • Natalizumab
  • Pharmacovigilance
  • Surveillance program

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Tedeschi, G., Amato, M. P., D'Alessandro, R., Drago, F., Milanese, C., Popoli, P., ... Mancardi, G. L. (2009). The pharmacovigilance program on natalizumab in Italy: 2 Years of experience. Neurological Sciences, 30(SUPPL. 2). https://doi.org/10.1007/s10072-009-0143-6

The pharmacovigilance program on natalizumab in Italy : 2 Years of experience. / Tedeschi, G.; Amato, M. P.; D'Alessandro, R.; Drago, F.; Milanese, C.; Popoli, P.; Rossi, P.; Savettieri, G.; Tola, M. R.; Vanacore, N.; Covezzoli, A.; De Rosa, M.; Comi, G.; Pozzilli, Carlo; Bertolotto, Antonio; Marrosu, Maria Giovanna; Grimaldi, Luigi M E; Piccinni, C.; Montanaro, N.; Periotto, Laura; Iommelli, Rosamaria; Addis, Antonio; Martini, Nello; Provinciali, L.; Mancardi, G. L.

In: Neurological Sciences, Vol. 30, No. SUPPL. 2, 2009.

Research output: Contribution to journalArticle

Tedeschi, G, Amato, MP, D'Alessandro, R, Drago, F, Milanese, C, Popoli, P, Rossi, P, Savettieri, G, Tola, MR, Vanacore, N, Covezzoli, A, De Rosa, M, Comi, G, Pozzilli, C, Bertolotto, A, Marrosu, MG, Grimaldi, LME, Piccinni, C, Montanaro, N, Periotto, L, Iommelli, R, Addis, A, Martini, N, Provinciali, L & Mancardi, GL 2009, 'The pharmacovigilance program on natalizumab in Italy: 2 Years of experience', Neurological Sciences, vol. 30, no. SUPPL. 2. https://doi.org/10.1007/s10072-009-0143-6
Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P et al. The pharmacovigilance program on natalizumab in Italy: 2 Years of experience. Neurological Sciences. 2009;30(SUPPL. 2). https://doi.org/10.1007/s10072-009-0143-6
Tedeschi, G. ; Amato, M. P. ; D'Alessandro, R. ; Drago, F. ; Milanese, C. ; Popoli, P. ; Rossi, P. ; Savettieri, G. ; Tola, M. R. ; Vanacore, N. ; Covezzoli, A. ; De Rosa, M. ; Comi, G. ; Pozzilli, Carlo ; Bertolotto, Antonio ; Marrosu, Maria Giovanna ; Grimaldi, Luigi M E ; Piccinni, C. ; Montanaro, N. ; Periotto, Laura ; Iommelli, Rosamaria ; Addis, Antonio ; Martini, Nello ; Provinciali, L. ; Mancardi, G. L. / The pharmacovigilance program on natalizumab in Italy : 2 Years of experience. In: Neurological Sciences. 2009 ; Vol. 30, No. SUPPL. 2.
@article{25511ec5497840b98fcdf71000484b21,
title = "The pharmacovigilance program on natalizumab in Italy: 2 Years of experience",
abstract = "At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6{\%}) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4{\%} of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10{\%} of the patients treated with natalizumab interrupted, for various different reasons, the therapy. Treatment was well tolerated and side effects were similar to those reported in the registrative studies. The majority of treated cases are stable or ameliorated.",
keywords = "Multiple sclerosis, Natalizumab, Pharmacovigilance, Surveillance program",
author = "G. Tedeschi and Amato, {M. P.} and R. D'Alessandro and F. Drago and C. Milanese and P. Popoli and P. Rossi and G. Savettieri and Tola, {M. R.} and N. Vanacore and A. Covezzoli and {De Rosa}, M. and G. Comi and Carlo Pozzilli and Antonio Bertolotto and Marrosu, {Maria Giovanna} and Grimaldi, {Luigi M E} and C. Piccinni and N. Montanaro and Laura Periotto and Rosamaria Iommelli and Antonio Addis and Nello Martini and L. Provinciali and Mancardi, {G. L.}",
year = "2009",
doi = "10.1007/s10072-009-0143-6",
language = "English",
volume = "30",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - The pharmacovigilance program on natalizumab in Italy

T2 - 2 Years of experience

AU - Tedeschi, G.

AU - Amato, M. P.

AU - D'Alessandro, R.

AU - Drago, F.

AU - Milanese, C.

AU - Popoli, P.

AU - Rossi, P.

AU - Savettieri, G.

AU - Tola, M. R.

AU - Vanacore, N.

AU - Covezzoli, A.

AU - De Rosa, M.

AU - Comi, G.

AU - Pozzilli, Carlo

AU - Bertolotto, Antonio

AU - Marrosu, Maria Giovanna

AU - Grimaldi, Luigi M E

AU - Piccinni, C.

AU - Montanaro, N.

AU - Periotto, Laura

AU - Iommelli, Rosamaria

AU - Addis, Antonio

AU - Martini, Nello

AU - Provinciali, L.

AU - Mancardi, G. L.

PY - 2009

Y1 - 2009

N2 - At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients treated with natalizumab interrupted, for various different reasons, the therapy. Treatment was well tolerated and side effects were similar to those reported in the registrative studies. The majority of treated cases are stable or ameliorated.

AB - At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases (88.6%) failed the therapy with beta interferon or glatiramer acetate and had relapses or accumulated disability during immunomodulating treatment, while 11.4% of patients enrolled in the surveillance study were not previously treated with immunomodulating therapies and had a rapidly evolving clinical course. Almost 10% of the patients treated with natalizumab interrupted, for various different reasons, the therapy. Treatment was well tolerated and side effects were similar to those reported in the registrative studies. The majority of treated cases are stable or ameliorated.

KW - Multiple sclerosis

KW - Natalizumab

KW - Pharmacovigilance

KW - Surveillance program

UR - http://www.scopus.com/inward/record.url?scp=74049140476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049140476&partnerID=8YFLogxK

U2 - 10.1007/s10072-009-0143-6

DO - 10.1007/s10072-009-0143-6

M3 - Article

C2 - 19882367

AN - SCOPUS:74049140476

VL - 30

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -